Anti-human leukocyte antigens and anti-major histocompatibility complex class I-related chain a antibody expression in kidney transplantation during a four-year follow-up

Chinese Medical Journal

Volumn 126, Issue 15, 2013, Pages 2815-2820

  He, Jun ^a   Li, Chen ^c   Yuan, Xiao Ni ^a   Zhang, Jiang Lei ^b   Li, Yang ^a   Wei, Xue Dong ^b   Hou, Jian Quan ^b  

^a Jiangsu Institute of Hematology   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c WUXI NO 2 PEOPLE S HOSPITAL   (China)

Author keywords

Antibody; Donor specific antibody; Graft function; Human leukocyte antigens; Kidney transplantation; Major histocompatibility complex class I related chain a; Non donor specific antibody

Indexed keywords

CREATININE; HLA A11 ANTIGEN; HLA A24 ANTIGEN; HLA ANTIGEN; HLA B13 ANTIGEN; HLA B37 ANTIGEN; HLA B7 ANTIGEN; HLA DQ2 ANTIGEN; HLA DQ8 ANTIGEN; HLA DR1 ANTIGEN; HLA DR4 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADULT; ARTICLE; COMPARATIVE STUDY; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION;

FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE;

EID: 84880962282     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20131143     Document Type: Article

References (28)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378-383.
2. Lachmann N, Terasaki PI, Budde K, Liefeldt L, Kahl A, Reinke P, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505-1513.
3. Lee PC, Chen YL, Chou TC, Wang WM, Wang JD, Hung CJ, et al. The clinical significance of human leukocyte antigen antibody development in kidney transplantation. Transplant Proc 2012; 44: 264-266.
4. Terasaki PI. A personal perspective: 100-year history of the humoral theory of transplantation. Transplantation 2012; 93: 751-756.
5. Mizutani K, Terasaki P, Rosen A, Esquenazi V, Miller J, Shih RN, et al. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 2005; 5: 2265-2272.
6. Zou Y, Heinemann FM, Grosse-Wilde H, Sireci G, Wang Z, Lavingia B, et al. Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the post-transplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry. Hum Immunol 2006; 67: 230-237.
7. Zou Y, Stastny P, Susal C, Dohler B, Opelz G. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007; 357: 1293-1300.
8. Lemy A, Andrien M, Lionet A, Labalette M, Noel C, Hiesse C, et al. Posttransplant major histocompatibility complex class I chain-related gene A antibodies and long-term graft outcomes in a multicenter cohort of 779 kidney transplant recipients. Transplantation 2012; 93: 1258-1264.
9. Cox ST, Stephens HA, Fernando R, Karasu A, Harber M, Howie AJ, et al. Major histocompatibility complex class I-related chain A allele mismatching, antibodies, and rejection in renal transplantation. Hum Immunol 2011; 72: 827-834.
10. Zhang M, Lu FM, Qu LX, He J, Yuan XN, Gu Y. Serum major-histocompatibility-complex class I-related chain A antibody detection for the evaluation of graft dysfunction in renal allograft recipients. Chin Med J 2011; 124: 2127-2131.
11. Wang YY, Hou JQ, He J, Yuan XN, Zhang JL, Wen DG. Effect of exogenous antigen on expression of major histocompatibility complex class I chain-related gene A in endothelial cells. J Clin Rehib Tiss Engi Res 2011; 15: 9999-10002.
12. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007; 7: 408-415.
13. Solgi G, Furst D, Mytilineos J, Pourmand G, Amirzargar AA. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA. Transpl Immunol 2012; 26: 81-87.
14. Hyun J, Park KD, Yoo Y, Lee B, Han BY, Song EY, et al. Effects of different sensitization events on HLA alloimmunization in solid organ transplantation patients. Transplant Proc 2012; 44: 222-225.
15. Ntokou IS, Iniotaki AG, Kontou EN, Darema MN, Apostolaki MD, Kostakis AG, et al. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules. Transpl Int 2011; 24: 1084-1093.
16. Martin L, Guignier F, Mousson C, Rageot D, Justrabo E, Rifle G. Detection of donor-specific anti-HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy. Transplantation 2003; 76: 395-400.
17. Martin L, Guignier F, Bocrie O, D'Athis P, Rageot D, Rifle G, et al. Detection of anti-HLA antibodies with flow cytometry in needle core biopsies of renal transplants recipients with chronic allograft nephropathy. Transplantation 2005; 79: 1459-1461.
18. Adeyi OA, Girnita AL, Howe J, Marrari M, Awadalla Y, Askar M, et al. Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches. Transpl Immunol 2005; 14: 53-62.
19. Terasaki PI, Cai J. Humoral theory of transplantation: further evidence. Curr Opin Immunol 2005; 17: 541-545.
20. Cai J, Terasaki PI, Mao Q, Pham T, El-Awar N, Lee JH, et al. Development of nondonor-specific HLA-DR antibodies in allograft recipients is associated with shared epitopes with mismatched donor DR antigens. Am J Transplant 2006; 6: 2947-2954.
21. Terasaki PI. Deduction of the fraction of immunologic and non-immunologic failure in cadaver donor transplants. Clin Transpl 2003: 449-452.
22. Opelz G. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005; 365: 1570-1576.
23. Mao Q, Terasaki PI, Cai J, Briley K, Catrou P, Haisch C, et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007; 7: 864-871.
24. Morath C, Beimler J, Opelz G, Scherer S, Schmidt J, Macher- Goeppinger S, et al. Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl Int 2012; 25: 506-517.
25. Guthoff M, Schmid-Horch B, Weisel KC, Haring HU, Konigsrainer A, Heyne N. Proteasome inhibition by bortezomib: Effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation. Transpl Immunol 2012; 26: 171-175.
26. Jin Q, Liu H, Song LY, Huang J, Chang Y, Zhang M, et al. Protein A immunoadsorption therapy in the highly sensitized kidney transplant candidates. Chin Med J 2011; 124: 780-782.
27. Wiebe C, Gibson IW, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157-1167.
28. Kanter Berga J, Pallardo Mateu LM, Beltran Catalan S, Puig Alcaraz N, Sancho Calabuig A, Gavela Martinez E, et al. Donor-specific HLA antibodies: risk factors and outcomes after kidney transplantation. Transplant Proc 2011; 43: 2154-2156.